OUL PARISTULIS

House of Representatives

General Assembly

File No. 72

February Session, 2022

Substitute House Bill No. 5260

House of Representatives, March 22, 2022

The Committee on Public Health reported through REP. STEINBERG of the 136th Dist., Chairperson of the Committee on the part of the House, that the substitute bill ought to pass.

AN ACT ESTABLISHING A RARE DISEASE COUNCIL.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 Section 1. (NEW) (Effective July 1, 2022) (a) There is established a
- 2 Connecticut Rare Disease Advisory Council. The council shall advise
- 3 and make recommendations to the Department of Public Health and
- 4 other state agencies, as appropriate, regarding the needs of persons in
- 5 the state living with a rare disease and such persons' caregivers. The
- 6 council may perform the following functions:
- 7 (1) Hold public hearings and otherwise make inquiries of and solicit
- 8 comments from the general public to assist with a study or survey of
- 9 persons living with a rare disease and such persons' caregivers and
- 10 health care providers;
- 11 (2) Consult with experts on rare diseases to develop policy
- 12 recommendations for improving patient access to quality medical care
- 13 in the state, affordable and comprehensive insurance coverage,
- 14 medications, medically necessary diagnostics, timely treatment and

15 other necessary services and therapies;

- (3) Research and make recommendations to the department, other state agencies, as necessary, and health carriers that provide services to persons living with a rare disease regarding the adverse impact that changes to health insurance coverage, drug formularies and utilization review, as defined in section 38a-591a of the general statutes, may have on the provision of treatment or care to persons living with a rare disease;
 - (4) Research and identify priorities related to treatments and services provided to persons living with a rare disease and develop policy recommendations regarding (A) safeguards and legal protections against discrimination and other practices that limit access to appropriate health care, services or therapies, and (B) planning for natural disasters and other public health emergencies;
 - (5) Research and make recommendations regarding improving the quality and continuity of care for persons living with a rare disease who are transitioning from pediatric to adult health care services;
 - (6) Research and make recommendations regarding the development of educational materials on rare diseases, including, but not limited to, online educational materials and a list of reliable resources for the department, other state agencies, as necessary, the public, persons living with a rare disease, such persons' families and caregivers, medical school students and health care providers; and
 - (7) Research and make recommendations for support and training resources for caregivers and health care providers of persons living with a rare disease.
- 41 (b) The council shall consist of the following members, who shall live 42 and work in the state:
- 43 (1) The Commissioner of Public Health, or the commissioner's designee;

45 (2) The Commissioner of Social Services, or the commissioner's designee;

- (3) The Insurance Commissioner, or the commissioner's designee, who may be the representative of a health carrier;
- (4) Two appointed by the Governor, one of whom shall be a representative of an association of hospitals in the state or an administrator of a hospital that provides health care to persons living with a rare disease, and one of whom shall be a physician licensed under chapter 370 of the general statutes who has expertise in the field of medical genetics;
 - (5) Two appointed by the Senate chairperson of the joint standing committee of the General Assembly having cognizance of matters relating to public health, one of whom shall be a representative of a patient advocacy group in the state representing all rare diseases, and one of whom shall be the family member or caregiver of a pediatric patient living with a rare disease;
 - (6) Two appointed by the House chairperson of the joint standing committee of the General Assembly having cognizance of matters relating to public health, one of whom shall be a representative of the biopharmaceutical industry in the state who is involved in rare disease research and therapy development, and one of whom shall be an adult living with a rare disease;
- (7) Two appointed by the Senate ranking member of the joint standing committee of the General Assembly having cognizance of matters relating to public health, one of whom shall be a member of the scientific community in the state who is engaged in rare disease research, and one of whom shall be the caregiver of a child or adult living with a rare disease; and
 - (8) Two appointed by the House ranking member of the joint standing committee of the General Assembly having cognizance of matters relating to public health, one of whom shall be a physician

licensed to practice under chapter 370 of the general statutes who treats persons living with a rare disease, and one of whom shall be a representative, family member or caregiver of a person living with a rare disease.

- (c) All initial appointments to the council shall be made not later than October 31, 2022. Any vacancy shall be filled by the appointing authority. Except for members of the council who represent state agencies, five of the members first appointed shall serve for a term of two years, five of such members shall serve for a term of three years and, thereafter, members shall serve for a term of two years. The Commissioner of Public Health shall determine which of the members first appointed shall serve for a term of two years and which of such members shall serve for a term of three years. The members of the council shall receive no compensation for their services but may be reimbursed for any necessary expenses incurred in the performance of their duties. The commissioner shall select an acting chairperson of the council from its members for the purpose of organizing the first council meeting. Such chairperson shall schedule and convene the first meeting, which shall be held not later than November 30, 2022. The members of the council shall appoint, by majority vote, a permanent chairperson and vice-chairperson during the first meeting of the council. Nothing in this subsection shall prohibit the reappointment of the chairperson, vice-chairperson or any member of the council to their position on the council.
- (d) The council shall meet in person or on a remote platform not less than six times between November 30, 2022, and October 31, 2023, as determined by the chairperson. Thereafter, the council shall meet quarterly in person or on a remote platform, as determined by the chairperson.
 - (e) The council shall provide opportunities at council meetings for the general public to make comments, hear updates from the council and provide input on council activities. The council shall create an Internet web site where meeting minutes, notices of upcoming meetings and

80

81

82

83

84

85 86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

- 109 feedback may be posted.
- 110 (f) The council shall be within the Department of Public Health for 111 administrative purposes only.
- 112 (g) Not later than one year after the date of its first meeting, and 113 annually thereafter, the council shall report to the Governor and, in 114 accordance with the provisions of section 11-4a of the general statutes, 115 to the joint standing committee of the General Assembly having 116 cognizance of matters relating to public health regarding its findings 117 and recommendations, including, but not limited to, (1) the council's 118 activities, research findings and any recommendations for proposed 119 legislative changes, and (2) any potential sources of funding for the 120 council's activities, including, but not limited to, grants, donations, 121 sponsorships or in-kind donations.

This act shall take effect as follows and shall amend the following sections:			5
Section 1	Iulu 1 2022	New section	

Statement of Legislative Commissioners:

In Section 1, "section 38a-581" was changed to "section 38a-591a" for accuracy.

PH Joint Favorable Subst. -LCO

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

OFA Fiscal Note

State Impact: None

Municipal Impact: None

Explanation

This bill, which establishes a 13-member Connecticut Rare Disease Advisory Council to advise state agencies on the needs of residents living with rare diseases, and their caregivers, is not anticipated to result in a fiscal impact to the state or municipalities.

PA 17-236 prohibits transportation allowances for taskforce members. This provision also applies to workgroups and councils.

The Out Years

State Impact: None

Municipal Impact: None

OLR Bill Analysis sHB 5260

AN ACT ESTABLISHING A RARE DISEASE COUNCIL.

SUMMARY

This bill establishes a 13-member Connecticut Rare Disease Advisory Council to advise and make recommendations to the Department of Public Health (DPH) and other state agencies on the needs of residents living with rare diseases, and their caregivers. The council is within DPH for administrative purposes only.

Under the bill, council members include the insurance, public health, and social services commissioners, or their designees, and 10 members appointed by the governor and the Public Health Committee leadership.

The bill requires the advisory council to meet in-person or remotely (1) at least six times between November 30, 2022, and October 31, 2023, and (2) quarterly thereafter, as determined by the chairperson. The council must also provide opportunities for the public to make comments, hear council updates, and provide input on council activities.

Lastly, the bill requires the council, starting by November 30, 2023, to annually report to the governor and the Public Health Committee on its findings and recommendations, including (1) council activities, research findings, and legislative recommendations and (2) potential funding sources for its activities, including grants, donations, sponsorships, or in-kind donations.

EFFECTIVE DATE: July 1, 2022

CONNECTICUT RARE DISEASE ADVISORY COUNCIL

Functions

Under the bill, the advisory council may do the following:

1. hold public hearings and otherwise solicit public comments and information to assist with studying or surveying residents with rare diseases, and their caregivers and health care providers;

- 2. consult with rare disease experts to develop policy recommendations for improving patient access to quality medical care in the state, affordable and comprehensive insurance coverage, medications, medically necessary diagnostics, timely treatment, and other necessary services and therapies;
- 3. research and make recommendations to DPH, other state agencies, and health carriers (i.e., insurers and HMOs) that provide services to those with rare diseases on the adverse impact that changes to health insurance coverage, drug formularies, and utilization review may have on providing treatment or care to these patients;
- 4. research and identify priorities related to rare disease treatments and services and develop policy recommendations on (a) safeguards and legal protections against discrimination and other practices that limit access to appropriate health care, services, or therapies and (b) planning for natural disasters and other public health emergencies;
- 5. research and make recommendations on improving the quality and continuity of care for those living with rare diseases who are transitioning from pediatric to adult health care services;
- 6. research and make recommendations on developing rare disease educational materials, including online materials and a list of reliable resources for DPH, other state agencies, the public, individuals living with a rare disease and their families and caregivers, medical students, and health care providers;
- 7. research and make recommendations on support and training

resources for caregivers and health care providers of individuals living with a rare disease.

Membership

Under the bill, the 13-member advisory council includes the insurance, public health, and social services commissioners, or their designees (which, for the insurance commissioner's designee, may be a health care representative) and the 10 appointed members listed in Table 1 below. All members must live and work in the state.

Table 1: Advisory Council Appointed Members

Appointing Authority	Qualifications	
Governor	One licensed physician with expertise in medical genetics	
	One hospital association representative or hospital administrator that provides health care to patients with rare diseases	
Public Health Committee Senate Chairperson	One representative of a patient advocacy group in the state for all rare diseases	
	One family member or caregiver of a pediatric patient living with a rare disease	
Public Health Committee House Chairperson	One representative of the biopharmaceutical industry in the state who is involved in rare disease research	
	One adult living with a rare disease	
Public Health Committee Senate Ranking Member	One member of the scientific community in the state who does rare disease research	
	One caregiver of a person living with a rare disease	
Public Health Committee House Ranking Member	One licensed physician who treats patients living with a rare disease	
	One representative, family member, or caregiver of a person living with a rare disease	

The bill requires appointing authorities to make initial appointments by October 31, 2022, and fill any vacancies.

Under the bill, five of the first-appointed members serve two-year terms, five members serve three-year terms, and all members serve two-

year terms thereafter. The DPH commissioner determines which of the first-appointed members serve two-year or three-year terms.

Members are not compensated for their services but may be reimbursed for necessary expenses.

Council Meetings and Leadership

Under the bill, the DPH commissioner selects the acting chairperson from among the council members to organize the first meeting, which must be held by November 30, 2022. The council members must then appoint a permanent chairperson and vice-chairperson by majority vote during the council's first meeting.

The bill also specifies that the chairperson, vice-chairperson, or any member may be reappointed to their position on the council.

During meetings, the bill requires the council to provide opportunities for the public to make comments, hear council updates, and provide input on council activities. The council must also create a website where it may post meeting minutes and notices, as well as feedback.

COMMITTEE ACTION

Public Health Committee

```
Joint Favorable
Yea 31 Nay 0 (03/11/2022)
```